Aviatrix Announces 10,000th “Aviatrix Certified Engineer” (ACE) Milestone and Introduces New Multi-Cloud Network Operations Certification
16.2.2021 17:00:00 EET | Business Wire | Press release
Aviatrix, the cloud network platform, today announced it has reached yet another significant milestone with its Aviatrix Certified Engineers (ACE) Program, while also launching a new multi-cloud network operations curriculum that builds on the basic cloud networking knowledge required to achieve ACE Multi-Cloud Networking Associate certification. The designation ACE Multi-Cloud Network Operations validates a cloud networking professional’s ability to successfully operate and manage multi-cloud networking and security services that support their organization’s needs. This course also introduces CI/CD and Infrastructure-as-a-Code (IaC) concepts, as more innovative solutions for operating cloud networking and security. Automation tools such as Terraform and the Aviatrix multi-cloud Terraform provider help operations an DevOps teams work closely together to deploy a repeatable and auditable infrastructure, leveraging a single CI/CCD pipeline.
With over 10,000 ACEs representing more than 2,500 companies, in over 110 countries worldwide, the Aviatrix ACE Program is the leading and most recognized multi-cloud networking technical certification. Specifically, this training program has helped cloud networking professionals and their companies close the skills gap, learn basic cloud service provider (CSP) constructs and how to add value by learning best practices for multi-cloud network architectures.
“Cloud networking is important but is also very complex. The Aviatrix ACE Program allows me to better understand the designs and limitations of all major cloud service providers (AWS, Azure, GCP, OCI, etc.,). This valuable education also helps architects and engineers design and build enterprise-class cloud networking solutions that meet enterprise-class security, performance, and compliance requirements. I strongly recommend this program to anyone interested in learning more about Hybrid or Multi-Cloud networking,” exclaimed Walter Lee, Sr. Software Engineer, at a leading global financial services company.
The ACE Program helps prepare an organization’s technical staff to lead and accelerate their transformation to cloud. The program is the first multi-cloud networking and security certification available to cloud practitioners, DevOps, networking staff, and security professionals. The ACE certification is designed for individuals who understand basic networking concepts and prepares engineers and operations staff with knowledge on (1) native cloud networking constructs in AWS, Azure, Google Cloud, and Oracle Cloud Infrastructure and (2) multi-cloud design patterns and concepts and (3) proficiency to plan and provision multi-cloud network use cases and architecture using the Aviatrix cloud network platform.
“The industry demand for the ACE Program over the past 12 months continues to exceed our expectations,” said Nauman Mustafa, Vice President Solutions Engineering, at Aviatrix. “With ACE, we provide the required training cloud networking professionals need to fully understand public-cloud networking constructs, service provider capabilities, different multi-cloud architectural design patterns, and how to apply this knowledge to their specific environment. Furthermore, our newly launched multi-cloud network operations course will enable the ACEs to successfully run, operate and efficiently manage their business-critical workloads in the cloud. They will also gain greater visibility, observability, and monitoring capabilities that go well beyond the basic operations and troubleshooting tools they get from their CSPs.”
Join the ACE Community Today!
To learn more about the ACE program, including the schedule for self-paced and instructor-led courses, course curriculum and other details, visit https://aviatrix.com/ace/. Or email us at ace@aviatrix.com to request more information.
About Aviatrix
Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005239/en/
Contact information
PR Contact:
Aviatrix
Dmitry Lipkin
dlipkin@aviatrix.com
408-888-2792
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom